Yanlan Li,1,2,* Xiangning Li,1,3,* Jiayao Qu,1,3 Dixian Luo,1,3 Zheng Hu1,3

1Translational Medicine Institute, the First Peoples Hospital of Chenzhou Affiliated to University of South China, Hunan 432000, Peoples Republic of China; 2Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, University of South China, Hunan 421001, Peoples Republic of China; 3National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First Peoples Hospital of Chenzhou, Hunan 432000, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Zheng Hu; Dixian LuoTranslational Medicine Institute, National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First Peoples Hospital of Chenzhou, Hunan 432000, Peoples Republic of ChinaTel/Fax +86 735 2343902Email hu48005@163.com; luodixian_2@163.com

Purpose: Colorectal cancer (CRC) is one of the major contributors to cancer mortality and morbidity. Finding strategies to fight against CRC is urgently required. Mutations in driver genes of APC or -catenin play an important role in the occurrence and progression of CRC. In the present study, we jointly apply CRISPR/Cas9-sgRNA system and Single-stranded oligodeoxynucleotide (ssODN) as templates to correct a heterozygous TCT deletion mutation of -catenin present in a colon cancer cell line HCT-116. This method provides a potential strategy in gene therapy for cancer.Methods: A Cas9/-catenin-sgRNA-eGFP co-expression vector was constructed and co-transfected with ssODN into HCT-116 cells. Mutation-corrected single-cell clones were sorted by FACS and judged by TA cloning and DNA sequencing. Effects of CRISPR/Cas9-mediated correction were tested by real-time quantitative PCR, Western blotting, CCK8, EDU dyeing and cell-plated clones. Moreover, the growth of cell clones derived tumors was analyzed at nude mice xenografts.Results: CRISPR/Cas9-mediated -catenin mutation correction resulted in the presence of TCT sequence and the re-expression of phosphorylation -catenin at Ser45, which restored the normal function of phosphorylation -catenin including reduction of the transportation of nuclear -catenin and the expression of downstream c-myc, survivin. Significantly reduced cell growth was observed in -catenin mutation-corrected cells. Mice xenografted with mutation-corrected HCT-116 cells showed significantly smaller tumor size than uncorrected xenografts.Conclusion: The data of this study documented that correction of the driven mutation by the combination of CRISPR/Cas9 and ssODN could greatly remedy the biological behavior of the cancer cell line, suggesting a potential application of this strategy in gene therapy of cancer.

Keywords: CRISPR/Cas9, ssODN, targeted gene editing, -catenin, colon cancer

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Cas9 Mediated Correction of -catenin Mutation and Restoring the | OTT - Dove Medical Press

Comments are closed.